InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,471.44
(
-0.21%
)
US TECH 100
19,181.00
(
-0.43%
)
Dow Jones
39,078.02
(
-0.22%
)
Brent Oil
84.83
(
-0.69%
)
Bitcoin
60,256.25
(
-2.18%
)
Post# of 252422
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119951
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 115600

Monday, 07/25/2011 11:35:53 AM

Monday, July 25, 2011 11:35:53 AM

Post# of 252422
MRX settles Solodyn patent case with Lupin, the last generic holdout:

http://www.reuters.com/article/2011/07/25/lupin-medicis-idUSL3E7IP22620110725

#msg-60357229 has a scorecard of the launch date and first-filer status for each dose of generic Soldyn.

Whatever one may think about Solodyn’s medical merit (or lack thereof), one has to marvel at how MRX has protected the Solodyn franchise from genericization. MRX’s detailing has been so effective that 90% of current branded+generic Solodyn scripts are for the non-legacy doses where MRX’s settlements ensure protection from generic competition for several years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up